Plasma medicine: cells, blood & tissue
Immune Cells Enhance Selectivity of Nanosecond-Pulsed DBD Plasma Against Tumor Cells
Plasma Medicine, 2017, 7(1): 85–96
DOI: 10.1615/PlasmaMed.2017019666 (opens in a new tab)
Cited by 28
Abstract
Cancer immunotherapy is a promising strategy that engages the patient’s immune system to kill cancer cells selectively while sparing normal tissue. Treatment of macrophages with a nanosecond-pulsed dielectric barrier discharge directly enhanced their cytotoxic activity against tumor cells but not normal cells. These results underscore the clinical potential of plasma for cancer immunotherapy.
How to cite
A. Lin, B. Truong, G. Fridman, A. A. Fridman, V. Miller (2017). Immune Cells Enhance Selectivity of Nanosecond-Pulsed DBD Plasma Against Tumor Cells. Plasma Medicine, 7(1): 85–96. https://doi.org/10.1615/PlasmaMed.2017019666